Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...

ANSWER: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a person’s own red blood cells. Unlike the usual type of autoimmune hemolytic ( “hemolytic” means ...

Cold autoimmune hemolytic anemia (c-AIHA), or cold agglutinin disease (CAD), most commonly affects adults between 40 and 80 years old. With CAD, antibodies activate at cooler temperatures and ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures.

FDA approves expanded label of Enjaymo ® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease. News release. January 25, 2023.

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million ...

Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has ...

Dear P.W.: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a person’s own red blood cells. Unlike the usual type of autoimmune hemolytic (”hemolytic ...

Dr. Roach: What are the symptoms for cold agglutinin disease, and how is it diagnosed? — P.W. Answer: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a ...